Breast Imaging - BI RADS Assessment and Recommendations

Key Points

• BI-RADS 0 means incomplete, not benign and not malignant.
• BI-RADS 3 is reserved for carefully selected probably benign findings and generally uses short-interval imaging rather than immediate biopsy.
• BI-RADS 4 and 5 usually require tissue diagnosis.
• BI-RADS 6 denotes a known biopsy-proven malignancy.
• Breast density is reported separately from the final assessment category.
• Radiologic-pathologic concordance is required after image-guided biopsy.
• A negative screening study does not automatically resolve a new concerning breast symptom.
• Every report should contain a specific management recommendation.

Algorithm

1. Determine whether the examination is screening or diagnostic and retrieve prior imaging.
2. Characterize the finding using modality-specific BI-RADS descriptors.
3. Assign the final assessment category.
4. For BI-RADS 0, obtain additional views, ultrasound, MRI, or prior comparison as appropriate.
5. For BI-RADS 3, schedule the recommended short-interval follow-up.
6. For BI-RADS 4 or 5, arrange image-guided core biopsy.
7. After biopsy, assess radiologic-pathologic concordance and escalate discordant benign results.
8. Return benign or resolved findings to the appropriate screening or risk-based surveillance program.

Clinical Synopsis & Reasoning

Breast imaging is most clinically useful when the report ends with a clear assessment and action. The ACR BI-RADS system provides standardized descriptors and categories so that a referring clinician can distinguish an incomplete examination from a benign finding and a biopsy recommendation. BI-RADS v2025 updates the ACR framework across mammography, ultrasound, MRI, contrast-enhanced mammography, and auditing while preserving the core category structure.

BI-RADS 0 means the examination is incomplete and additional imaging or prior studies are needed. It should not be interpreted as a positive cancer result. BI-RADS 1 is negative; BI-RADS 2 is a benign finding. BI-RADS 3 indicates a probably benign finding with an expected malignancy probability of no more than about 2% and usually calls for short-interval surveillance rather than immediate biopsy. BI-RADS 4 is suspicious and subdivided into 4A, 4B, and 4C to communicate increasing concern. BI-RADS 5 is highly suggestive of malignancy. BI-RADS 6 is used for biopsy-proven malignancy before definitive treatment.

Descriptors differ by modality but include mass shape, margins, density or echogenicity, calcifications, architectural distortion, asymmetry, enhancement, and associated findings. Breast density is reported separately because it affects both risk and mammographic sensitivity. A comparison with prior imaging can convert an apparent abnormality into a stable benign finding or demonstrate meaningful interval change.

Treatment Strategy & Disposition

Management should follow the final category and clinical context. BI-RADS 0 requires completion of the diagnostic workup. BI-RADS 1 or 2 returns the patient to routine screening unless symptoms require separate evaluation. BI-RADS 3 generally receives imaging surveillance, often beginning at 6 months, with continued stability confirming benign behavior. BI-RADS 4 and 5 lesions usually undergo image-guided core biopsy.

Radiologic-pathologic concordance is essential after biopsy. A benign pathology result does not end the workup if it fails to explain a suspicious imaging abnormality. Discordant benign biopsy may require repeat image-guided biopsy or surgical excision. Conversely, a high-risk lesion can prompt surgical or multidisciplinary review even when not frankly malignant. Clip placement and postbiopsy imaging support future localization and concordance.

A palpable mass, nipple discharge, skin change, or other concerning symptom can require diagnostic evaluation even after a recent negative screening mammogram. Do not use a screening BI-RADS category as a substitute for symptom-directed assessment. High-risk patients may need MRI screening in addition to mammography according to risk guidelines. Communication should include the category, recommendation, timing, and responsibility for follow-up.

Epidemiology / Risk Factors

• Breast imaging is performed for screening, symptoms, high-risk surveillance, and treatment planning.
• Breast cancer risk rises with age and varies with genetics, reproductive factors, prior atypia, radiation exposure, and breast density.
• Most recalled screening findings are not cancer.
• Standardized BI-RADS reporting improves quality auditing and consistency across practices.

Investigations

Core Categories

Pharmacology

Prognosis / Complications

• BI-RADS 1 and 2 findings have no imaging evidence of malignancy.
• BI-RADS 3 findings are expected to remain benign with surveillance.
• Earlier tissue diagnosis of BI-RADS 4 or 5 lesions can identify curable cancer before advanced symptoms develop.
• Outcome after malignancy depends on tumor biology, stage, receptor status, and treatment rather than BI-RADS category alone.

Patient Education / Counseling

• Explain that a callback after screening is common and does not mean cancer is present.
• State the exact next step and timing, especially for BI-RADS 0 and 3.
• After biopsy, tell the patient that pathology must be checked for concordance with the imaging.
• Patients with a new palpable mass or bloody nipple discharge should seek evaluation even if recent screening was normal.
• Encourage patients to obtain prior imaging when moving between health systems because comparison can prevent unnecessary procedures.

Notes

BI-RADS is both a communication system and a quality-assurance system. The category should be consistent with the language in the report and the management recommendation. A report that calls a lesion 'highly suspicious' but assigns BI-RADS 3 creates unsafe ambiguity.

The 2025 update modernizes modality-specific descriptors, but clinicians should continue to anchor interpretation in the familiar final categories and radiologic-pathologic concordance principles.

References

1. American College of Radiology: BI-RADS v2025 — Link
2. ACR: BI-RADS v2025 Manual Released — Link